Back pain stem cell injection, page-70

"It was around August 2015 when Meso 1^st tabled the Tier 1 & Tier 2 applications.
Tier 2s include Crohns ; Heart attack , spinal fusion and BMT. Since then ..at every presentation ( at least 10), it has been made very clear that the Company is concentrating on the following Tier 1’s

ALL $Bn dollar potential blockbuster

• CHF ( class 2-3 and Class 4)
• DDD
• RA

Plus

• aGVHD (where FDA agreed for a 60 patient open label trial)

In contrast BMT has a small $$n market application and reach. When you have limited cash, you allocate your dollars to the Blockbusters."


Which begs the questions:

1. Why did it take them almost 10 years to decide to focus on billion dollar blockbusters?
2. Why not go for the billion dollar blockbusters from the very start?

And the most obvious question of them all:

3. If bone marrow was so close to commercialisation, why did they simply not continue with this until the point of revenue generation?

Having a product selling in the market would have validated MSB's development program like little else could, and would have had partners beating a path to MSB's doors, waving chequebooks aloft.

And it couldn't have been a issue of money, because MSB had hundreds of millions of dollars in the bank at the time.

Besides, the strategic focus on Tier 1 products only came into being some 5 years later.

So, your excuse of "In contrast BMT has a small $$n market application and reach. When you have limited cash, you allocate your dollars to the Blockbusters" doesn't past muster, I'm afraid.